Study on her2-positive early-stage breast cancer treatment
Part of Cancer clinical trials.
This study looks at how well a new test can help manage her2-positive early-stage breast cancer. It includes patients who have had treatment before or after surgery with trastuzumab and possibly pertuzumab.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have early-stage breast cancer (stage I to III) that can be removed with surgery.
- Your tumor is her2-positive, meaning it has a specific protein that helps it grow.
- You received treatment with trastuzumab (and possibly pertuzumab) before or after surgery.
- You have been seen by your doctor for at least 3 years after your surgery.
- You have not been diagnosed with any other invasive cancer before this breast cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the genetic details of HER2-positive breast cancer to help find subtypes and improve future treatments. It does not test a new drug but collects information from your tumor tissue to learn more about the disease.
This study looks at different treatment plans after surgery for people with HER2-positive breast cancer who still have cancer cells remaining after initial chemo and trastuzumab. It aims to see which approach helps improve outcomes.
This trial tests a neoadjuvant (before surgery) treatment plan for people with early-stage HER2-positive breast cancer. The goal is to see if a personalized approach can improve outcomes.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
This trial tests a combination of two targeted therapies given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see if this approach is safe and effective for early-stage breast cancer.
Hear when a new Breast Cancer Early Stage Breast Cancer (Stage 1-3) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.